Staar Surg Stock Price, News & Analysis

STAAR Surgical Company (NASDAQ: STAA) will release its financial results for Q1 2023 on May 3, 2023, after market close. The company is known for developing implantable lenses to enhance vision and has sold over 2 million ICLs in over 75 countries. A conference call will follow at 4:30 PM Eastern to discuss operational progress and financial outcomes. Interested parties can access the call via phone or the live webcast from STAAR's investor relations website. A replay of the call will be available for a week afterward. With a commitment to ophthalmic surgery for over 40 years, STAAR continues to innovate and expand its reach in the vision correction market.

STAAR Surgical Company (NASDAQ: STAA) announces the appointment of Warren Foust as Chief Operating Officer and Magda Michna, Ph.D., as Chief Clinical, Regulatory and Medical Affairs Officer. This move underscores the company's commitment to growth in the ophthalmic sector. Foust, previously with Johnson & Johnson Vision, brings extensive experience in surgical operations. Michna joins from AcuFocus, Inc., with a strong background in clinical and regulatory affairs. CEO Tom Frinzi emphasizes their roles in expanding the market for EVO ICL lenses.

STAAR Surgical Company (NASDAQ: STAA) reported robust financial results for Q4 and FY 2022, showcasing a strong growth trajectory. Q4 net sales rose to $64.0 million, a 9% increase year-over-year, driven by a 15% rise in ICL sales to $61.2 million. Fiscal 2022 net sales reached $284.4 million, up 23%, with ICL sales soaring 27%. Gross margins improved to 77.7% in Q4 and 78.5% for the year. Net income for Q4 was $5.9 million ($0.12 per share), reflecting a year-over-year increase. Looking ahead, STAAR anticipates approximately $340 million in total ICL sales for FY 2023, representing a 26% growth. The company's cash reserves totaled $225.5 million at year-end.

STAAR Surgical Company (NASDAQ: STAA) will release its financial results for the fourth quarter and fiscal year ending December 30, 2022, on February 21, 2023, after the market closes. A conference call will follow at 4:30 p.m. Eastern to discuss the results. The conference can be accessed via phone or through a live webcast on the company's website. STAAR specializes in designing and manufacturing implantable lenses for ophthalmic surgery, having sold over 2 million ICLs globally.

STAAR Surgical Company (NASDAQ: STAA) has partnered with actress Peyton List to promote its EVO Implantable Collamer® Lenses for myopia correction. List, who underwent the EVO procedure in December 2022, highlights the advantages of not needing contacts or glasses, achieving 20/20 vision post-surgery. The EVO lenses do not remove corneal tissue and have minimal downtime, making them a favorable option compared to LASIK. With myopia's global prevalence projected to reach 50% by 2050, STAAR aims to inspire others to consider EVO for their vision needs.